Bring the whole
system into the
room
I work with companies, investors, healthcare organizations, and international patients who need clinical depth, scientific fluency, and a builder’s perspective. Five ways to work together. Engagements are confidential and never published.
Clinical leadership for companies that need a CMO before they can hire one.
For health technology, oncology AI, diagnostics, and precision medicine companies from seed through Series B. I take defined ownership of clinical strategy, evidence and validation plans, regulatory and guideline positioning, clinical advisory recruitment, and the medical credibility investors and health systems require. One to two days a week, structured around a defined scope and a defined term.
Fractional Medical Director engagements are available to health systems, telehealth platforms, and specialty practices that need an oncology quality, protocol, and program lead. The engaging organization holds licensure and malpractice coverage for any clinical oversight.
Open to inquiries.
For decisions where clinical, scientific, and commercial realities collide.
Scientific and clinical advisory boards, corporate boards, and standing advisory relationships across precision medicine, clinical AI, biomarker strategy, and care delivery. Investor diligence on oncology and health technology deals, priced per engagement. Engagements are shaped around the decision, not a standard consulting package.
Investment Counsel
A standing advisory relationship for family offices and investors active in oncology and health technology: deal screening, one deep diligence each quarter, and a monthly strategy call. Confidential, conflict-checked, and shaped around the portfolio.
Open to inquiries.
A specialist’s read, on the clock.
Expert calls, structured market research, and oncology and hematology consultations for pharmaceutical, biotechnology, diagnostics, and investment firms. Available directly or through the major expert networks. Hourly or per-project.
Expert witness and independent medical review in oncology and hematology are available to counsel on both sides.
Open to inquiries.
Ideas built for consequential rooms.
Keynotes, panels, and executive conversations drawn from the rooms I have worked in: the clinic, the NIH-funded lab, the drug industry, and the academic center.
-
Cancer Is Not an Event
The case for predictive cancer care, and what it takes to read risk years before a diagnosis.
-
A Pattern Is Not a Decision
Where AI belongs in medicine, where it does not, and how to build clinical intelligence physicians can stand behind.
-
The Missing Decades
Survivorship is oncology’s largest unbuilt system. What comes after treatment, and who is responsible for it.
-
What the Dying Teach the Living
Stories from the bedside on fear, cure, meaning, and how to live.
Oral Late-Breaking Abstract, ASCO Annual Meeting. Additional presentations at AACR and ASH.
Open to inquiries.
Additional perspective when the decision matters.
A focused oncology or hematology consultation for international patients and families seeking additional perspective outside their home care system.
-
01International patients
-
02Families seeking another perspective
-
03Complex oncology / hematology decisions